17 December 2018 - Unlike other prescription chronic idiopathic constipation treatments, Motegrity works differently by enhancing natural movements of the colon muscle, known as peristalsis.

Shire has announced that the U.S. FDA has approved Motegrity (prucalopride), a once-daily, oral treatment option for adults with chronic idiopathic constipation.

The efficacy of once-daily treatment with Motegrity was evaluated in six double-blind, placebo-controlled, randomised, multi-centre clinical studies lasting 12 weeks (studies 1-5) or 24 weeks (study 6).1 Of the 2,484 patients, most were female (76%) and Caucasian (76%), with an average age of 47 (+/- 16 years).

Read Shire press release